MARKET

DXCM

DXCM

Dexcom Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

276.00
-5.32
-1.89%
Opening 09:59 05/26 EDT
OPEN
284.07
PREV CLOSE
281.32
HIGH
284.07
LOW
272.58
VOLUME
122.89K
TURNOVER
20.82M
52 WEEK HIGH
659.45
52 WEEK LOW
267.57
MARKET CAP
27.08B
P/E (TTM)
134.98
1D
5D
1M
3M
1Y
5Y
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space
Dexcom stock tumbled Tuesday on rumors that it's in talks to acquire insulin pump-maker Insulet. Insulet stock, on the other hand, popped.
Investor's Business Daily · 1d ago
Hot Stocks: UBER drops on cautious comment; INMB regulatory setback; CTRN rises on earnings; DXCM falls
Uber (NYSE:UBER) was among the standout decliners on an overall weak day for the market, dropping in Tuesday's midday trading following a cautious analyst comment.  INmune Bio (INMB) also suffered
Seekingalpha · 1d ago
DexCom - Insulet buyout deal unlikely, Bank of America says
Commenting on the reports that the medical device company DexCom (NASDAQ:DXCM) is in talks to acquire the insulin pump maker Insulet (NASDAQ:PODD), a group of analysts at Bank of America
Seekingalpha · 2d ago
Insulet's stock is up on Bloomberg report that it may be acquired by Dexcom
Shares of Insulet Corp. gained 9.9% in premarket trading on Tuesday, the day after Bloomberg reported that the company is in talks to be acquired by Dexcom Inc. , citing anonymous sources. Dexcom's stock was down 7.1% before the market opened on Tuesday. A...
marketwatch.com · 2d ago
Sector Update: Health Care
MT Newswires · 2d ago
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO, May 23, 2022--DexCom, Inc. (NASDAQ:DXCM) today announced that Brice Bobzien, Senior Vice President, Finance, will present an update on the company at the Piper Sandler Ophthalmology and Diabetes Symposium on Wednesday, May 25, 2022 at 1:00 p.m. ...
Business Wire · 3d ago
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
Zacks · 6d ago
Are Options Traders Betting on a Big Move in DexCom (DXCM) Stock?
Investors need to pay close attention to DexCom (DXCM) stock based on the movements in the options market lately.
Zacks · 05/19 12:44
More
No Data
Learn about the latest financial forecast of DXCM. Analyze the recent business situations of Dexcom Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

55.56%Strong Buy
33.33%Buy
11.11%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DXCM stock price target is 540.38 with a high estimate of 600.00 and a low estimate of 480.00.
High600.00
Average540.38
Low480.00
Current 276.01
EPS
Actual
Estimate
0.220.450.670.89
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 1.12K
Institutional Holdings: 104.10M
% Owned: 106.09%
Shares Outstanding: 98.13M
TypeInstitutionsShares
Increased
335
5.50M
New
190
1.72M
Decreased
265
6.72M
Sold Out
49
1.72M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.21%
Healthcare Equipment & Supplies
+0.04%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Sayer
Chief Financial Officer/Executive Vice President
Jereme Sylvain
Chief Human Resource Officer/Executive Vice President
Sadie Stern
Executive Vice President/Chief Technology Officer
Jacob Leach
Executive Vice President/Managing Director
Steven Pacelli
Executive Vice President
Donald Abbey
Executive Vice President
Andrew Balo
Executive Vice President
Michael Brown
Executive Vice President
Paul Flynn
Executive Vice President
Chad Patterson
Executive Vice President
Barry Regan
Senior Vice President/Chief Information Officer
Shelly Selvaraj
Senior Vice President/Chief Risk Officer
Sumi Shrishrimal
Senior Vice President
Matthew Dolan
Lead Director/Independent Director
Mark Foletta
Independent Director
Steven Altman
Independent Director
Nicholas Augustinos
Independent Director
Richard Collins
Independent Director
Karen Dahut
Independent Director
Bridgette Heller
Independent Director
Barbara Kahn
Independent Director
Kyle Malady
Independent Director
Jay Skyler
Independent Director
Eric Topol
No Data
No Data
About DXCM
Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.

Webull offers kinds of DexCom, Inc. stock information, including NASDAQ:DXCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DXCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DXCM stock methods without spending real money on the virtual paper trading platform.